drugset / Trial / NCT04191941
Treatment of Hematological Malignancy With Novel CAR-T Cells.
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, early phase I study, to determine the safety and efficacy of Novel CAR-T cell therapy in Hematological Malignancy treatment.
Timeline
- Start
- 2019-09-01
- Primary completion
- 2021-08-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Novel CAR-T | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |